Results 151 to 160 of about 52,710 (257)

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, EarlyView.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Granzyme B and melittin in cancer immunotherapy: molecular mechanisms and therapeutic perspectives in head and neck cancers. [PDF]

Front Immunol
Majchrzak A, Lewandowski F, Hrynkiewicz R, Poniewierska-Baran A, Bębnowska D, Niedźwiedzka-Rystwej P.   +5 more
europepmc   +1 more source

Traditional Chinese Medicine for lung cancer: Mechanisms, clinical evidence, and future perspectives

Precision Medical Sciences, EarlyView.
Graphical abstract represents the risk factors for lung cancer, TCM efficacy and clinical outcomes to future challenges. Abstract Lung cancer remains a leading cause of global cancer mortality. Despite advances in conventional treatments such as surgery, chemotherapy, targeted therapy, and immunotherapy, challenges including drug resistance, toxicity ...
Zhangdeng Chen, Liujun Bao
wiley   +1 more source

Granzyme B as a potential biological target in toxic encephalopathy: A big data-based exploratory analysis. [PDF]

Medicine (Baltimore)
Liu L, Wang J, Liu C.
europepmc   +1 more source

Granzyme K: A new frontier in systemic lupus erythematosus

Rheumatology &Autoimmunity, EarlyView.
The role of Granzyme K in the pathogenesis of systemic lupus erythematosus and its clinical translational significance. Abstract Systemic lupus erythematosus (SLE) is a complex autoimmune disorder driven by dysregulated adaptive and innate immunity and aberrant complement activity.
Zhongyu Chen, Yunjing Pu, Peihui Yang, Qinghuan Zhu, Haojun Long, Danqi Deng   +5 more
wiley   +1 more source

Peptide‐based responsive molecular fluorescent probes for precision oncology

Responsive Materials, EarlyView.
Peptide‐based responsive fluorescent probes have emerged as adaptive functional materials for precision tumor theranostics, combining tumor‐selective recognition, programmable stimulus responsiveness, and modular tunability. They enable high‐contrast imaging, intraoperative guidance, real‐time monitoring, and multimodal applications, while next ...
Xing Wang, Wen Liu, Jiahao Zhang, Wanqi Wang, Zhicheng Jin, Yuqi Tang, Quan Li   +6 more
wiley   +1 more source

Granzyme B contributes to subretinal fibrosis in neovascular age-related macular degeneration by modulating inflammation and epithelial-mesenchymal transition. [PDF]

J Neuroinflammation
Yoo HS, Chakravarthy H, Xi J, Cui J, Ai Z, Hosseini A, Song J, Tan N, Ma N, Zhou C, Li B, Bell R, Haegert A, Le Bihan S, Ju MJ, Granville DJ, Matsubara JA.   +16 more
europepmc   +1 more source

Cancer Vaccine Development: Toward Artificial Intelligence‐Assisted Personalized Cell Membrane Nanovaccine

Small, EarlyView.
Cancer nanovaccines have emerged as promising alternatives to conventional cancer vaccines, which have shown limited clinical efficacy. In particular, cell membrane nanoparticle‐based nanovaccines can offer high biocompatibility and immunogenicity while preserving tumor antigens, including antigen repertoires.
Munsik Kim, Ilkoo Noh
wiley   +1 more source

Granzyme B PET Imaging Enables Early Assessment of Immunotherapy Response in a Humanized Melanoma Mouse Model. [PDF]

Pharmaceuticals (Basel)
Summer P, Gallon N, Bulmer N, Mahmood U, Heidari P.   +4 more
europepmc   +1 more source

Redox‐responsive dual‐drug nanomedicine integrating cisplatin and trypsin for synergistic reversal of tumor chemoresistance

Smart Molecules, EarlyView.
This study presents a novel glutathione‐activatable prodrug nanomedicine (cRGD‐PEG‐PGlu‐NP (ssTrypsin & CDDP)) that co‐encapsulates cisplatin and a masked protease to combat cisplatin resistance. The dual‐drug system selectively targets resistant tumor cells, enhancing the efficacy of cisplatin while minimizing systemic toxicity.
Xiaolan Yin, Qi Wang, Ming Zhang, Cheng Zhang, Qixian Chen, Haidong Li, Yan Zhao, Yue Wang, Jingyun Wang, Liuwei Zhang, Hongyan Cui   +10 more
wiley   +1 more source